Last reviewed · How we verify

NCT00016380

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Completed Phase 3 Last updated 3 April 2020
What this trial tests

Phase 3 trial testing dexamethasone in Cancer in 211 participants. Completed in 10 February 2009.

Timeline
28 February 2001
Primary endpoint
30 April 2004
10 February 2009

Quick facts

Lead sponsorNCIC Clinical Trials Group
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Maskingnone
Primary purposesupportive care
Enrollment211
Start date28 February 2001
Primary completion30 April 2004
Estimated completion10 February 2009
Sites14 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

NCIC Clinical Trials Group

Who can join

Adults 16 to 120, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by radiation therapy. PURPOSE: This randomized phase III trial is comparing how well ondansetron works with or without dexamethasone in preventing vomiting in patients with cancer who are receiving radiation therapy to the upper abdomen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of dexamethasone

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00016380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing